Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422699 | 0.81 | CYP2D6 (0.50) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL5568199 | 0.78 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL17108650 | 0.77 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL16330601 | 0.77 | KDM4E (0.33) | SMN1; SMN2TSHR | |
| SCHEMBL19756511 | 0.75 | CYP2D6 (0.41) | CYP2D6ALDH1A1 | |
| SCHEMBL25917688 | 0.75 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL26184568 | 0.75 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL24235262 | 0.75 | CYP2D6 (0.55) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL27391327 | 0.74 | CYP2D6 (0.39) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL23560004 | 0.73 | CYP2D6 (0.58) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2475/4885SMN1; SMN2 2516/4885PIK3CD 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.